Objectives: The resazurin microtitre plate assay (REMA) was evaluated to determine the susceptibility of Mycobacterium tuberculosis to pyrazinamide, and was compared with the broth microdilution method (BMM), the absolute concentration method (ACM) and pyrazinamidase (PZase) determination.
Introduction
Multidrug-resistant tuberculosis (MDR-TB) is highly prevalent worldwide, especially in East Europe and Central Asia where .20% of new cases are resistant to multiple drugs. 1 Early diagnosis and susceptibility testing are of paramount importance to avoid TB evolution and establish early and effective treatment. The Lowenstein -Jensen (LJ) proportion method, routinely used in some countries, such as Brazil, for the detection of resistance to antituberculous drugs is laborious, time-consuming and has low reproducibility due to the difficulties with the technique and mycobacterial growth in acidic pH. In fact, the acidic environment may inhibit 50% of colonies, with a considerable decrease in colony size when compared with a neutral pH environment. 2 Susceptibility testing in liquid medium has been proposed for the detection of resistance in Mycobacterium tuberculosis at the shortest reading time, namely the Microplate Alamar blue assay (MABA), 3 the broth microdilution method (BMM), 4 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) 5 and resazurin microtitre plate assay (REMA). 6 When compared with the LJ proportion method, the above colorimetric methods are faster, highly sensitive and specific for detection of resistance to isoniazid and rifampicin. 7 REMA is a simple and secure method within the context of the above-mentioned tests. 6 It employs oxy-reduction of resazurin as a colorimetric indicator to determine resistance to drugs and obtain the MIC. The test is inexpensive when compared with the LJ proportion method. Furthermore, in contrast to the molecular methods, expensive equipment is not required. However, studies undertaken with REMA have only evaluated the resistance of M. tuberculosis isolates to isoniazid and rifampicin, owing to difficulties in the technique for pyrazinamide. We aimed to: (i) evaluate the REMA method for the determination of susceptibility of M. tuberculosis to pyrazinamide; and (ii) compare it with the BMM, the absolute concentration method (ACM) and pyrazinamidase (PZase) determination.
Methods
Thirty-four M. tuberculosis clinical isolates (26 susceptible and 8 resistant to pyrazinamide by the LJ proportion method, pH 5.5, with a concentration of 100 mg/L as the cut-off for resistance) were selected from the mycobacteria collection of the Clinical Bacteriology Laboratory in the Department of Clinical Analyses and Biomedicine of the State University of Maringá, Maringá, PR, Brazil. The pyrazinamide-susceptible reference strain M. tuberculosis H37Rv ATCC 27294 and the pyrazinamide-resistant reference strain Mycobacterium bovis AN5 were used as controls in the susceptibility tests. Mycobacterium avium (Central Laboratory, PR, Brazil) and M. bovis AN5 were used as positive and negative controls for the PZase assay, respectively. Automated DNA sequencing of a 1200 bp segment, including the entire pncA open reading frame as well as its regulatory region, had been previously carried out by Barco et al.
8 in pyrazinamide-resistant M. tuberculosis isolates.
REMA was carried out in triplicate, as previously described by Palomino et al. 6 Middlebrook 7H9 medium (Difco Laboratories, Detroit, MI, USA), supplemented with oleic acid/bovine albumin/dextrose/catalase (OADC) enrichment (BBL/Becton-Dickinson, Sparks, MD, USA), was prepared according to the manufacturer's instructions; the pH was adjusted to 6.0 8 and pyrazinamide was diluted to obtain final concentrations of 12.5 -3200 mg/L. One hundred microlitres of each standardized bacterial inoculum with a turbidity equivalent to that of a 1 McFarland standard and diluted 1:20 in Middlebrook 7H9 medium, pH 6.0, was inoculated. A growth control containing no drug and a sterile control without bacteria were also used. The plates were covered with lids, placed in a plastic bag and incubated at 358C at normal atmosphere for 7 days. After that, 30 mL of freshly prepared 0.01% resazurin solution (Acros, Morris Plains, NJ, USA) was added to each well and the plates were re-incubated at 358C for 24 h. The MIC was defined as the lowest pyrazinamide concentration that prevented colour change from blue to pink due to resazurin reduction. The ACM was carried out in triplicate according to Kent and Kubica 9 in LJ slant medium (Difco Laboratories, Detroit, MI, USA), pH 5.2, using pyrazinamide concentrations from 12.5 to 3200 mg/L. A mycobacterial growth control for each M. tuberculosis isolate was carried out in LJ slant medium, at pH 5.2 and 6.8 without pyrazinamide. 8 The MIC was expressed as the lowest concentration of the drug that inhibited mycobacterial growth. The BMM was performed in triplicate, as previously described by Leite et al. 4 Pyrazinamide dilutions were performed to obtain concentrations of 12.5 -3200 mg/L. The MIC was defined as the lowest pyrazinamide concentration that visually exhibited no growth. Isolates for which the MIC was ≤100 mg/L were considered susceptible to pyrazinamide by REMA, the ACM and the BMM. 8 PZase activity was evaluated according to Wayne, 10 modified by Morlock et al., 2 using Dubos broth medium (Difco Laboratories, Detroit, MI, USA) with 100 mg/L pyrazinamide.
The software EpiInfo w (CDC, USA), version 3.32, was employed for data tabulation and the software Open Info w , version 2.3, was employed for data analysis at a significance level of 5%. The association of REMA, the BMM and PZase determination was assessed using Fisher's exact test.
Results and discussion Table 1 shows the MICs of pyrazinamide, PZase activities and molecular characteristics for the eight pyrazinamide-resistant M. tuberculosis clinical isolates and reference strains. Two M. tuberculosis isolates (1137 and 3224) failed to register any growth by the BMM. One isolate (3224) showed a PZase positive result and no mutation in the pncA open reading frame or in its putative regulatory region. Table 2 shows the MICs of pyrazinamide and PZase activities for the 26 pyrazinamide-susceptible M. tuberculosis clinical isolates and reference strains. 
Detection of pyrazinamide resistance in Mycobacterium tuberculosis
The time required for detection of resistance to pyrazinamide was 8, 20, 28 and 7 days for REMA, the BMM, the ACM and PZase determination, respectively. The performance of REMA, the BMM and PZase determination for detection of resistance to pyrazinamide was determined using the ACM as the standard. REMA and BMM sensitivity and specificity were complete (100%). In the case of PZase determination, sensitivity and specificity were 87.50% and 100%, respectively. There were no significant differences between the tests (P,0.001).
The need for standardization of a reliable and easy method for detection of resistance to pyrazinamide in M. tuberculosis is mandatory. As reported in previous studies with isoniazid and rifampicin, 6 results with REMA obtained for pyrazinamide resistance detection totally agreed in sensitivity and specificity with those obtained with the ACM. Besides the high specificity and sensitivity, it should be emphasized that results obtained by REMA were given within 8 days. Owing to its ease of reading, Taneja and Tyagi 11 compared results obtained by REMA for the detection of resistance to isoniazid, rifampicin, ethambutol and other drugs by visual and fluorometric reading. The authors showed total agreement between the two reading methods. REMA is confirmed to be inexpensive since no specialized apparatus is needed. This fact decreases assay costs and dangers in the formation of aerosols during the manipulation of microplates in fluorometric reading.
When the 100 mg/L pyrazinamide concentration employed in previous assays as a cut-off for resistance 8 is taken into consideration, REMA allowed easy resistance discrimination for all M. tuberculosis clinical isolates investigated. However, the analysis was only undertaken with eight pyrazinamide-resistant isolates and all showed MICs of ≥800 mg/L by the ACM and the BMM. It should be emphasized that further studies are required with M. tuberculosis resistant to pyrazinamide with lower MIC values for a better evaluation of REMA for the detection of low resistance to pyrazinamide. Similar to the evaluation by Leite et al., 4 the BMM produced good results with regard to sensitivity and specificity for the detection of resistance to pyrazinamide. The MICs of pyrazinamide were lower for most M. tuberculosis isolates studied when compared with those obtained using the ACM carried out in solid medium. This fact may be explained by difficulties in BMM reading, inoculum concentration and greater contact between the mycobacteria and the drug. Another disadvantage with regard to the employment of BMM in the determination of sensitivity to pyrazinamide, is the incubation time required for reading, normally an average of 20 days.
The usefulness of the PZase assay lies in its speed, simplicity and high specificity; however, it has some limitations, as resistance to pyrazinamide may be through mechanisms other than mutation in the pncA gene. In our study, 87.50% of pyrazinamide-resistant isolates showed mutations in the pncA open reading frame or in its regulatory region, which may cause lack of PZase.
The analysis of mutations in pncA may provide fast and useful information on resistance to pyrazinamide, with most resistant M. tuberculosis isolates showing mutations in this gene. 8 However, equipment and reagents used in this methodology are highly expensive and not easily and routinely accessible to detect pyrazinamide resistance in some laboratories.
In summary, the present work showed that, in spite of the small number of resistant isolates evaluated, REMA was efficient in detecting pyrazinamide resistance. It is faster, low-cost and easy to perform and interpret, and does not need special equipment or reagents. REMA should be evaluated on an extended panel of M. tuberculosis clinical isolates for a better understanding of its utility in differentiating pyrazinamide-resistant from pyrazinamide-susceptible M. tuberculosis.
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